Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Recruiting 6Completed 5Terminated 3Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 6Hematologic Neoplasms 5Breast Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Glioma 3Colorectal Neoplasms 3Prostatic Neoplasms 2Neoplasms by Site 2Motor Activity 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Anxiety Disorders 2Anatomic Stage I Breast Cancer AJCC v8 2Uveal Melanoma 1Uterine Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomatitis 1Stomach Neoplasms 1Smoking Cessation 1Small Cell Lung Carcinoma 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × Standard of Care × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

Phase 2 Terminated
142 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

NCT01010334 2013-08-14

Comparison of Standard of Care or Treatment on Protocol

New Mexico Cancer Research Alliance

Phase NA Terminated
13 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡